CHARLOTTE, N.C., May 22, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 38th Annual Deutsche Bank Health Care Conference at 4:50 PM on Wednesday, May 29, 2013 in Boston.
Nick Riehle, Vice President Administration and Chief Financial Officer will provide a corporate update and an overview of the Northera™ (droxidopa) development program.
Mr. Riehle's presentation will be webcast live and archived for 30 days on Chelsea's website, www.chelseatherapeutics.com.
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information about the Company, visit www.chelseatherapeutics.com